Date | Dividend Per Share | Free Cash Flow Per Share | Return on Assets (ROA) | Return on Equity (ROE) |
---|
CEO | Mr. Yonehiro Matsumura |
IPO Date | Feb. 14, 2013 |
Location | Japan |
Headquarters | 431-7 Nishiyama |
Employees | 22 |
Sector | Health Care |
Industries |
MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email